Sponsors
Personalis, Tempus Partner to Commercialize Blood-Based Minimal Residual Disease Test
Tempus will market Personalis' NeXT Personal Dx liquid biopsy assay while Personalis completes its clinical validation in more indications.
Germany to Test Genomics-Based Precision Medicine for Cancer, Rare Disease in National Pilot Project
Premium
With reimbursement from public health insurance, the "model project" will run for at least five years and examine the utility of genomic sequencing for advanced cancer and rare disease patients.
Liquid Biopsy Comparison Highlights Cell-Free RNA, Multiomic Approaches for Detecting Gastrointestinal Cancers
Researchers used a range of cell-free DNA or cell-free RNA analysis methods to detect possible blood plasma markers for colorectal or stomach cancer.
Cervical Cancer Multiomic Study Uncovers Informative Intratumor Heterogeneity States
With single-cell, spatial, and experimental approaches, researchers defined eight "meta-programs" linked to the tumor immune microenvironment and clinical features.
Nanopore Sequencing-Based Method Provides Copy Number Analysis for Brain Tumors in Under Two Hours
Premium
Developed by Dartmouth researchers, the method can be performed in under two hours, offering the potential to classify a tumor in the course of surgery.